Abstract
Systematization of literature data on the use of thyroid hormones in patients with heart failure and the results of own research are given. The therapy of levothyroxine in patients with heart failure, at the moment of time, remains still an "open book". Several questions remain unsolved: regimen, doses and schedule of levothyroxine use, consequences of this therapy. It is necessary to conduct large, multicenter, prospective, placebo-controlled studies, which should provide information on the safety and impact of levothyroxine on the long-term prognosis of these patients. Our study shows that the long-term administration of levothyroxine in patients with heart failure and accompanying hypothyroidism has a dose-dependent positive effect on the value of the left ventricular ejection fraction and on the course of heart pathology. The maximum ejection fraction of the left ventricle is observed in patients who took the drug in a dose > 1.2 μg/kg. The use of the drug in a dose > 0.53 μg/kg leads to a probable decrease in the frequency of re-hospitalization within 2 years due to decompensation of heart failure.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
